These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 37701966)
1. Next-generation proteomics technologies in Alzheimer's disease: from clinical research to routine diagnostics. Weiner S; Blennow K; Zetterberg H; Gobom J Expert Rev Proteomics; 2023; 20(7-9):143-150. PubMed ID: 37701966 [TBL] [Abstract][Full Text] [Related]
2. Mass spectrometry-based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids. Korecka M; Shaw LM J Neurochem; 2021 Oct; 159(2):211-233. PubMed ID: 34244999 [TBL] [Abstract][Full Text] [Related]
3. Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics. Liu Y; Qing H; Deng Y Int J Mol Sci; 2014 May; 15(5):7865-82. PubMed ID: 24806343 [TBL] [Abstract][Full Text] [Related]
4. Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease. Robinson RA; Amin B; Guest PC Adv Exp Med Biol; 2017; 974():21-48. PubMed ID: 28353223 [TBL] [Abstract][Full Text] [Related]
5. Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases. Cilento EM; Jin L; Stewart T; Shi M; Sheng L; Zhang J J Neurochem; 2019 Nov; 151(4):397-416. PubMed ID: 30474862 [TBL] [Abstract][Full Text] [Related]
8. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. Hampel H; Lista S; Khachaturian ZS Alzheimers Dement; 2012 Jul; 8(4):312-36. PubMed ID: 22748938 [TBL] [Abstract][Full Text] [Related]
13. Targeted and Untargeted Proteomics Approaches in Biomarker Development. Sobsey CA; Ibrahim S; Richard VR; Gaspar V; Mitsa G; Lacasse V; Zahedi RP; Batist G; Borchers CH Proteomics; 2020 May; 20(9):e1900029. PubMed ID: 31729135 [TBL] [Abstract][Full Text] [Related]
14. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R; Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606 [TBL] [Abstract][Full Text] [Related]
15. Validating blood tests as a possible routine diagnostic assay of Alzheimer's disease. Kodosaki E; Zetterberg H; Heslegrave A Expert Rev Mol Diagn; 2023; 23(12):1153-1165. PubMed ID: 38018372 [TBL] [Abstract][Full Text] [Related]
16. Evolving Relevance of Neuroproteomics in Alzheimer's Disease. Lista S; Zetterberg H; O'Bryant SE; Blennow K; Hampel H Methods Mol Biol; 2017; 1598():101-115. PubMed ID: 28508359 [TBL] [Abstract][Full Text] [Related]
17. MS-DAP Platform for Downstream Data Analysis of Label-Free Proteomics Uncovers Optimal Workflows in Benchmark Data Sets and Increased Sensitivity in Analysis of Alzheimer's Biomarker Data. Koopmans F; Li KW; Klaassen RV; Smit AB J Proteome Res; 2023 Feb; 22(2):374-386. PubMed ID: 36541440 [TBL] [Abstract][Full Text] [Related]
18. Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective. Findeisen P; Neumaier M Clin Chem Lab Med; 2009; 47(6):666-84. PubMed ID: 19445650 [TBL] [Abstract][Full Text] [Related]
19. Targeted proteomics for quantification of histone acetylation in Alzheimer's disease. Zhang K; Schrag M; Crofton A; Trivedi R; Vinters H; Kirsch W Proteomics; 2012 Apr; 12(8):1261-8. PubMed ID: 22577027 [TBL] [Abstract][Full Text] [Related]
20. Advances in mass spectrometry-based cancer research and analysis: from cancer proteomics to clinical diagnostics. Timms JF; Hale OJ; Cramer R Expert Rev Proteomics; 2016 Jun; 13(6):593-607. PubMed ID: 27109265 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]